{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:06:57Z","timestamp":1793506017825,"version":"4.5.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T00:00:00Z","timestamp":1645401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T00:00:00Z","timestamp":1645401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1038\/s41401-022-00858-x","type":"journal-article","created":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T11:15:07Z","timestamp":1645442107000},"page":"2302-2312","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Activation of the endocannabinoid system mediates cardiac hypertrophy induced by rosiglitazone"],"prefix":"10.1038","volume":"43","author":[{"given":"Ya-han","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei-lei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan-ping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,21]]},"reference":[{"key":"858_CR1","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.2337\/diabetes.54.10.2838","volume":"54","author":"S Engeli","year":"2005","unstructured":"Engeli S, B\u00f6hnke J, Feldpausch M, Gorzelniak K, Janke J, B\u00e1tkai S, et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes. 2005;54:2838\u201343.","journal-title":"Diabetes"},{"key":"858_CR2","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/clc.21962","volume":"35","author":"S Singla","year":"2012","unstructured":"Singla S, Sachdeva R, Mehta JL. Cannabinoids and atherosclerotic coronary heart disease. Clin Cardiol. 2012;35:329\u201335.","journal-title":"Clin Cardiol"},{"key":"858_CR3","doi-asserted-by":"publisher","first-page":"e009099","DOI":"10.1161\/JAHA.118.009099","volume":"7","author":"N Alfulaij","year":"2018","unstructured":"Alfulaij N, Meiners F, Michalek J, Small-Howard AL, Turner HC, Stokes AJ. Cannabinoids, the heart of the matter. J Am Heart Assoc. 2018;7:e009099.","journal-title":"J Am Heart Assoc"},{"key":"858_CR4","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/j.1365-2826.2008.01677.x","volume":"20","author":"R Sarzani","year":"2008","unstructured":"Sarzani R. Endocannabinoids, blood pressure and the human heart. J Neuroendocrinol. 2008;20:58\u201362.","journal-title":"J Neuroendocrinol"},{"key":"858_CR5","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.tips.2012.03.002","volume":"33","author":"F Montecucco","year":"2012","unstructured":"Montecucco F, Di Marzo V. At the heart of the matter: the endocannabinoid system in cardiovascular function and dysfunction. Trends Pharmacol Sci. 2012;33:331\u201340.","journal-title":"Trends Pharmacol Sci"},{"key":"858_CR6","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.lfs.2013.03.014","volume":"92","author":"GD Duerr","year":"2013","unstructured":"Duerr GD, Heinemann JC, Dunkel S, Zimmer A, Lutz B, Lerner R, et al. Myocardial hypertrophy is associated with inflammation and activation of endocannabinoid system in patients with aortic valve stenosis. Life Sci. 2013;92:976\u201383.","journal-title":"Life Sci"},{"key":"858_CR7","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.jacc.2007.03.057","volume":"50","author":"P Mukhopadhyay","year":"2007","unstructured":"Mukhopadhyay P, B\u00e1tkai S, Rajesh M, Czifra N, Harvey-White J, Hask\u00f3 G, et al. Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity. J Am Coll Cardiol. 2007;50:528\u201336.","journal-title":"J Am Coll Cardiol"},{"key":"858_CR8","doi-asserted-by":"publisher","first-page":"H1689","DOI":"10.1152\/ajpheart.00538.2007","volume":"293","author":"S B\u00e1tkai","year":"2007","unstructured":"B\u00e1tkai S, Mukhopadhyay P, Harvey-White J, Kechrid R, Pacher P, Kunos G. Endocannabinoids acting at CB1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats. Am J Physiol-Heart Circ Physiol. 2007;293:H1689\u2013H95.","journal-title":"Am J Physiol-Heart Circ Physiol"},{"key":"858_CR9","doi-asserted-by":"publisher","first-page":"716","DOI":"10.2337\/db11-0477","volume":"61","author":"M Rajesh","year":"2012","unstructured":"Rajesh M, B\u00e1tkai S, Kechrid M, Mukhopadhyay P, Lee W-S, Horv\u00e1th B, et al. Cannabinoid 1 receptor promotes cardiac dysfunction, oxidative stress, inflammation, and fibrosis in diabetic cardiomyopathy. Diabetes. 2012;61:716\u201327.","journal-title":"Diabetes"},{"key":"858_CR10","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.yjmcc.2015.06.010","volume":"85","author":"C-Y Lin","year":"2015","unstructured":"Lin C-Y, Hsu Y-J, Hsu S-C, Chen Y, Lee H-S, Lin S-H, et al. CB1 cannabinoid receptor antagonist attenuates left ventricular hypertrophy and Akt-mediated cardiac fibrosis in experimental uremia. J Mol Cell Cardiol. 2015;85:249\u201361.","journal-title":"J Mol Cell Cardiol"},{"key":"858_CR11","doi-asserted-by":"crossref","unstructured":"Mukhopadhyay P, Rajesh M, B\u00e1tkai S, Patel V, Kashiwaya Y, Liaudet L, et al. CB1 cannabinoid receptors promote oxidative stress and cell death in murine models of doxorubicin-induced cardiomyopathy and in human cardiomyocytes. Cardiovasc Res. 2009;cvp369.","DOI":"10.1093\/cvr\/cvp369"},{"key":"858_CR12","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/sj.bjp.0705313","volume":"139","author":"P Lepicier","year":"2003","unstructured":"Lepicier P, Bouchard JF, Lagneux C, Lamontagne D. Endocannabinoids protect the rat isolated heart against ischaemia. Br J Pharmacol. 2003;139:805\u201315.","journal-title":"Br J Pharmacol"},{"key":"858_CR13","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.yjmcc.2008.12.014","volume":"46","author":"F Montecucco","year":"2009","unstructured":"Montecucco F, Lenglet S, Braunersreuther V, Burger F, Pelli G, Bertolotto M, et al. CB(2) cannabinoid receptor activation is cardioprotective in a mouse model of ischemia\/reperfusion. J Mol Cell Cardiol. 2009;46:612\u201320.","journal-title":"J Mol Cell Cardiol"},{"key":"858_CR14","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.1096\/fj.09-129478","volume":"23","author":"N Defer","year":"2009","unstructured":"Defer N, Wan J, Souktani R, Escoubet B, Perier M, Caramelle P, et al. The cannabinoid receptor type 2 promotes cardiac myocyte and fibroblast survival and protects against ischemia\/reperfusion-induced cardiomyopathy. FASEB J. 2009;23:2120\u201330.","journal-title":"FASEB J"},{"key":"858_CR15","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s00395-014-0425-x","volume":"109","author":"GD Duerr","year":"2014","unstructured":"Duerr GD, Heinemann JC, Suchan G, Kolobara E, Wenzel D, Geisen C, et al. The endocannabinoid-CB2 receptor axis protects the ischemic heart at the early stage of cardiomyopathy. Basic Res Cardiol. 2014;109:425.","journal-title":"Basic Res Cardiol"},{"key":"858_CR16","doi-asserted-by":"publisher","first-page":"12953","DOI":"10.1074\/jbc.270.22.12953","volume":"270","author":"JM Lehmann","year":"1995","unstructured":"Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem. 1995;270:12953\u20136.","journal-title":"J Biol Chem"},{"key":"858_CR17","first-page":"1070","volume":"46","author":"A Ibrahimi","year":"1994","unstructured":"Ibrahimi A, Teboul L, Gaillard D, Amri EZ, Ailhaud G, Young P, et al. Evidence for a common mechanism of action for fatty acids and thiazolidinedione antidiabetic agents on gene expression in preadipose cells. Mol Pharmacol. 1994;46:1070\u20136.","journal-title":"Mol Pharmacol"},{"key":"858_CR18","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1253\/circj.CJ-11-0060","volume":"75","author":"N Wang","year":"2011","unstructured":"Wang N, Yin R, Liu Y, Mao G, Xi F. Role of peroxisome proliferator-activated receptor-GAMMA in atherosclerosis\u2014an update. Circ J. 2011;75:528\u201335.","journal-title":"Circ J"},{"key":"858_CR19","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/clpt.2011.43","volume":"89","author":"A Winterstein","year":"2011","unstructured":"Winterstein A. Rosiglitazone and the risk of adverse cardiovascular outcomes. Clin Pharmacol Ther. 2011;89:776\u20138.","journal-title":"Clin Pharmacol Ther"},{"key":"858_CR20","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1056\/NEJMoa072761","volume":"356","author":"SE Nissen","year":"2007","unstructured":"Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457\u201371.","journal-title":"N Engl J Med"},{"key":"858_CR21","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1001\/jama.298.10.1189","volume":"298","author":"S Singh","year":"2007","unstructured":"Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA. 2007;298:1189\u201395.","journal-title":"JAMA"},{"key":"858_CR22","doi-asserted-by":"publisher","first-page":"l7078","DOI":"10.1136\/bmj.l7078","volume":"368","author":"JD Wallach","year":"2020","unstructured":"Wallach JD, Wang K, Zhang AD, Cheng D, Grossetta Nardini HK, Lin H, et al. Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses. BMJ. 2020;368:l7078.","journal-title":"BMJ"},{"key":"858_CR23","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1080\/10408444.2017.1351420","volume":"48","author":"MA Davidson","year":"2018","unstructured":"Davidson MA, Mattison DR, Azoulay L, Krewski D. Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future. Crit Rev Toxicol. 2018;48:52\u2013108.","journal-title":"Crit Rev Toxicol"},{"key":"858_CR24","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1056\/NEJM199910213411706","volume":"341","author":"JJ Hunter","year":"1999","unstructured":"Hunter JJ, Chien KR. Signaling pathways for cardiac hypertrophy and failure. N Engl J Med. 1999;341:1276\u201383.","journal-title":"N Engl J Med"},{"key":"858_CR25","unstructured":"Pharmaceuticals T. Actos [piogltiazone hydrochloride] prescribing information. 2007. http:\/\/www.actos.com\/actospro\/prescribniginto.aspx. 2007."},{"key":"858_CR26","unstructured":"GlaxoSmithKline. Avandia (rosiglitazone maleate) [prescribing information]. 2007. http:\/\/us.gsk.com\/products\/assets\/us_avandia.pdf."},{"key":"858_CR27","doi-asserted-by":"publisher","first-page":"6047","DOI":"10.1210\/en.2006-1559","volume":"148","author":"S Sena","year":"2007","unstructured":"Sena S, Rasmussen IR, Wende AR, McQueen AP, Theobald HA, Wilde N, et al. Cardiac hypertrophy caused by peroxisome proliferator-activated receptor-gamma agonist treatment occurs independently of changes in myocardial insulin signaling. Endocrinology. 2007;148:6047\u201353.","journal-title":"Endocrinology"},{"key":"858_CR28","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ejphar.2006.03.058","volume":"538","author":"AJ Edgley","year":"2006","unstructured":"Edgley AJ, Thalen PG, Dahllof B, Lanne B, Ljung B, Oakes ND. PPARgamma agonist induced cardiac enlargement is associated with reduced fatty acid and increased glucose utilization in myocardium of Wistar rats. Eur J Pharmacol. 2006;538:195\u2013206.","journal-title":"Eur J Pharmacol"},{"key":"858_CR29","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1161\/01.RES.0000179226.34112.6d","volume":"97","author":"SZ Duan","year":"2005","unstructured":"Duan SZ, Ivashchenko CY, Russell MW, Milstone DS, Mortensen RM. Cardiomyocyte-specific knockout and agonist of peroxisome proliferator-activated receptor-gamma both induce cardiac hypertrophy in mice. Circ Res. 2005;97:372\u20139.","journal-title":"Circ Res"},{"key":"858_CR30","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.ejphar.2005.05.032","volume":"517","author":"M Bouaboula","year":"2005","unstructured":"Bouaboula M, Hilairet S, Marchand J, Fajas L, Le Fur G, Casellas P. Anandamide induced PPARgamma transcriptional activation and 3T3-L1 preadipocyte differentiation. Eur J Pharmacol. 2005;517:174\u201381.","journal-title":"Eur J Pharmacol"},{"key":"858_CR31","doi-asserted-by":"publisher","first-page":"218","DOI":"10.4062\/biomolther.2014.137","volume":"23","author":"S Ahn","year":"2015","unstructured":"Ahn S, Yi S, Seo WJ, Lee MJ, Song YK, Baek SY, et al. A cannabinoid receptor agonist N-arachidonoyl dopamine inhibits adipocyte differentiation in human mesenchymal stem cells. Biomol Ther. 2015;23:218\u201324.","journal-title":"Biomol Ther"},{"key":"858_CR32","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1111\/j.1365-2567.2008.02838.x","volume":"125","author":"M Roche","year":"2008","unstructured":"Roche M, Kelly JP, O\u2019Driscoll M, Finn DP. Augmentation of endogenous cannabinoid tone modulates lipopolysaccharide-induced alterations in circulating cytokine levels in rats. Immunology. 2008;125:263\u201371.","journal-title":"Immunology"},{"key":"858_CR33","doi-asserted-by":"crossref","first-page":"425289","DOI":"10.1155\/2009\/425289","volume":"2009","author":"SE O\u2019Sullivan","year":"2009","unstructured":"O\u2019Sullivan SE, Kendall DA, Randall MD. Time-dependent vascular effects of Endocannabinoids mediated by peroxisome proliferator-activated receptor gamma (PPARgamma). PPAR Res. 2009;2009:425289.","journal-title":"PPAR Res"},{"key":"858_CR34","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1124\/mol.105.019117","volume":"70","author":"CE Rockwell","year":"2006","unstructured":"Rockwell CE, Snider NT, Thompson JT, Vanden Heuvel JP, Kaminski NE. Interleukin-2 suppression by 2-arachidonyl glycerol is mediated through peroxisome proliferator-activated receptor gamma independently of cannabinoid receptors 1 and 2. Mol Pharmacol. 2006;70:101\u201311.","journal-title":"Mol Pharmacol"},{"key":"858_CR35","doi-asserted-by":"publisher","first-page":"14919","DOI":"10.1523\/JNEUROSCI.1165-14.2014","volume":"34","author":"J Zhang","year":"2014","unstructured":"Zhang J, Hu M, Teng Z, Tang YP, Chen C. Synaptic and cognitive improvements by inhibition of 2-AG metabolism are through upregulation of microRNA-188-3p in a mouse model of Alzheimer\u2019s disease. J Neurosci. 2014;34:14919\u201333.","journal-title":"J Neurosci"},{"key":"858_CR36","doi-asserted-by":"publisher","first-page":"e49915","DOI":"10.1371\/journal.pone.0049915","volume":"8","author":"L Li","year":"2013","unstructured":"Li L, Zhang Z-G, Lei H, Wang C, Wu L-P, Wang J-Y, et al. Angiotensin II reduces cardiac AdipoR1 expression through AT1 receptor\/ROS\/ERK1\/2\/c-Myc pathway. PLoS ONE. 2013;8:e49915.","journal-title":"PLoS ONE"},{"key":"858_CR37","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1124\/jpet.110.167635","volume":"334","author":"X Wang","year":"2010","unstructured":"Wang X, Liu X, Zhan Y, LaVallie ER, DiBlasio-Smith L, Collins-Racie L, et al. Pharmacogenomic, physiological, and biochemical investigations on safety and efficacy biomarkers associated with the peroxisome proliferator-activated receptor-\u03b3 activator rosiglitazone in rodents: a translational medicine investigation. J Pharmacol Exp Ther. 2010;334:820\u20139.","journal-title":"J Pharmacol Exp Ther"},{"key":"858_CR38","doi-asserted-by":"publisher","first-page":"5634","DOI":"10.1021\/pr400587y","volume":"12","author":"Y Liu","year":"2013","unstructured":"Liu Y, Yan X, Mao G, Fang L, Zhao B, Liu Y, et al. Metabonomic profiling revealed an alteration in purine nucleotide metabolism associated with cardiac hypertrophy in rats treated with thiazolidinediones. J Proteome Res. 2013;12:5634\u201341.","journal-title":"J Proteome Res"},{"key":"858_CR39","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s10456-015-9474-5","volume":"18","author":"G Mao","year":"2015","unstructured":"Mao G, Liu Y, Fang X, Liu Y, Fang L, Lin L, et al. Tumor-derived microRNA-494 promotes angiogenesis in non-small cell lung cancer. Angiogenesis. 2015;18:373\u201382.","journal-title":"Angiogenesis"},{"key":"858_CR40","doi-asserted-by":"publisher","first-page":"H533","DOI":"10.1152\/ajpheart.00107.2005","volume":"289","author":"P Pacher","year":"2005","unstructured":"Pacher P, B\u00e1tkai S, Osei-Hyiaman D, Offert\u00e1ler L, Liu J, Harvey-White J, et al. Hemodynamic profile, responsiveness to anandamide, and baroreflex sensitivity of mice lacking fatty acid amide hydrolase. Am J Physiol-Heart Circ Physiol. 2005;289:H533\u2013H41.","journal-title":"Am J Physiol-Heart Circ Physiol"},{"key":"858_CR41","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ab.2012.09.031","volume":"432","author":"B Han","year":"2013","unstructured":"Han B, Wright R, Kirchhoff AM, Chester JA, Cooper BR, Davisson VJ, et al. Quantitative LC\u2013MS\/MS analysis of arachidonoyl amino acids in mouse brain with treatment of FAAH inhibitor. Anal Biochem. 2013;432:74\u201381.","journal-title":"Anal Biochem"},{"key":"858_CR42","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1007\/s11427-009-0136-y","volume":"52","author":"B Yan","year":"2009","unstructured":"Yan B, A J, Hao H, Wang G, Zhu X, Zha W, et al. Metabonomic phenotype Identification of \u201cheart blood stasis obstruction pattern\u201d and \u201cqi and yin deficiency pattern\u201d of myocardial ischemia rat models. Sci China C Life Sci. 2009;52:1081\u201390.","journal-title":"Sci China C Life Sci"},{"key":"858_CR43","doi-asserted-by":"publisher","first-page":"34176","DOI":"10.1074\/jbc.M203436200","volume":"277","author":"N Wang","year":"2002","unstructured":"Wang N, Verna L, Chen NG, Chen J, Li H, Forman BM, et al. Constitutive activation of peroxisome proliferator-activated receptor-gamma suppresses pro-inflammatory adhesion molecules in human vascular endothelial cells. J Biol Chem. 2002;277:34176\u201381.","journal-title":"J Biol Chem"},{"key":"858_CR44","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1124\/jpet.302.1.73","volume":"302","author":"AH Lichtman","year":"2002","unstructured":"Lichtman AH, Hawkins EG, Griffin G, Cravatt BF. Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo. J Pharmacol Exp Ther. 2002;302:73\u20139.","journal-title":"J Pharmacol Exp Ther"},{"key":"858_CR45","doi-asserted-by":"publisher","first-page":"237","DOI":"10.2174\/092986607780090829","volume":"14","author":"BS Basavarajappa","year":"2007","unstructured":"Basavarajappa BS. Critical enzymes involved in endocannabinoid metabolism. Protein Pept Lett. 2007;14:237.","journal-title":"Protein Pept Lett"},{"key":"858_CR46","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1194\/jlr.R024505","volume":"53","author":"JV Huang","year":"2012","unstructured":"Huang JV, Greyson CR, Schwartz GG. PPAR-\u03b3 as a therapeutic target in cardiovascular disease: evidence and uncertainty Thematic Review Series: new lipid and lipoprotein targets for the treatment of cardiometabolic diseases. J Lipid Res. 2012;53:1738\u201354.","journal-title":"J Lipid Res"},{"key":"858_CR47","doi-asserted-by":"publisher","first-page":"8260","DOI":"10.1021\/jm301204r","volume":"55","author":"BR Hoffmann","year":"2012","unstructured":"Hoffmann BR, El-Mansy MF, Sem DS, Greene AS. Chemical proteomics-based analysis of off-target binding profiles for rosiglitazone and pioglitazone: clues for assessing potential for cardiotoxicity. J Med Chem. 2012;55:8260\u201371.","journal-title":"J Med Chem"},{"key":"858_CR48","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.tips.2008.03.001","volume":"29","author":"V Di Marzo","year":"2008","unstructured":"Di Marzo V, Maccarrone M. FAAH and anandamide: is 2-AG really the odd one out? Trends Pharmacol Sci. 2008;29:229\u201333.","journal-title":"Trends Pharmacol Sci"},{"key":"858_CR49","doi-asserted-by":"publisher","first-page":"350","DOI":"10.4103\/0975-7406.84435","volume":"3","author":"P Cunha","year":"2011","unstructured":"Cunha P, Romao AM, Mascarenhas-Melo F, Teixeira HM, Reis F. Endocannabinoid system in cardiovascular disorders\u2014new pharmacotherapeutic opportunities. J Pharm Bioallied Sci. 2011;3:350\u201360.","journal-title":"J Pharm Bioallied Sci"},{"key":"858_CR50","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ceca.2013.12.005","volume":"55","author":"LT Al Kury","year":"2014","unstructured":"Al Kury LT, Voitychuk OI, Ali RM, Galadari S, Yang K-HS, Howarth FC, et al. Effects of endogenous cannabinoid anandamide on excitation\u2013contraction coupling in rat ventricular myocytes. Cell Calcium. 2014;55:104\u201318.","journal-title":"Cell Calcium"},{"key":"858_CR51","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1134\/S1062359007010049","volume":"34","author":"A Krylatov","year":"2007","unstructured":"Krylatov A, Maslov L, Ermakov SY, Lasukova O, Barzakh E, Crawford D, et al. Significance of cardiac cannabinoid receptors in regulation of cardiac rhythm, myocardial contractility, and electrophysiologic processes in heart. Biol Bull. 2007;34:28\u201335.","journal-title":"Biol Bull"},{"key":"858_CR52","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0014-2999(00)00396-4","volume":"404","author":"M Oz","year":"2000","unstructured":"Oz M, Tchugunova YB, Dunn SM. Endogenous cannabinoid anandamide directly inhibits voltage-dependent Ca2+ fluxes in rabbit T-tubule membranes. Eur J Pharmacol. 2000;404:13\u201320.","journal-title":"Eur J Pharmacol"},{"key":"858_CR53","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nrm1155","volume":"4","author":"MJ Berridge","year":"2003","unstructured":"Berridge MJ, Bootman MD, Roderick HL. Calcium signalling: dynamics, homeostasis and remodelling. Nat Rev Mol Cell Biol. 2003;4:517\u201329.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"858_CR54","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.freeradbiomed.2010.11.002","volume":"50","author":"P Mukhopadhyay","year":"2011","unstructured":"Mukhopadhyay P, Horv\u00e1th B, Rajesh M, Matsumoto S, Saito K, B\u00e1tkai S, et al. Fatty acid amide hydrolase is a key regulator of endocannabinoid-induced myocardial tissue injury. Free Radic Biol Med. 2011;50:179\u201395.","journal-title":"Free Radic Biol Med"},{"key":"858_CR55","doi-asserted-by":"publisher","first-page":"4587024","DOI":"10.1155\/2020\/4587024","volume":"2020","author":"JA Garza-Cervantes","year":"2020","unstructured":"Garza-Cervantes JA, Ramos-Gonzalez M, Lozano O, Jerjes-Sanchez C, Garcia-Rivas G. Therapeutic applications of cannabinoids in cardiomyopathy and heart failure. Oxid Med Cell Longev. 2020;2020:4587024.","journal-title":"Oxid Med Cell Longev"},{"key":"858_CR56","doi-asserted-by":"crossref","unstructured":"Kaschina E. Cannabinoid CB1\/CB2 receptors in the heart: expression, regulation, and function. In: Cannabinoids in health and disease. Cannabinoids in Health and Disease. 2016.","DOI":"10.5772\/62822"},{"key":"858_CR57","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1001\/jama.295.7.761","volume":"295","author":"FX Pi-Sunyer","year":"2006","unstructured":"Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J, Group, et al. Effect of rimonabant, a cannabinoid\u22121 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA. 2006;295:761\u201375.","journal-title":"JAMA"},{"key":"858_CR58","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s00395-009-0034-2","volume":"104","author":"SY Lim","year":"2009","unstructured":"Lim SY, Davidson SM, Yellon DM, Smith CC. The cannabinoid CB1 receptor antagonist, rimonabant, protects against acute myocardial infarction. Basic Res Cardiol. 2009;104:781\u201392.","journal-title":"Basic Res Cardiol"},{"key":"858_CR59","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.beem.2008.10.003","volume":"23","author":"F Borrelli","year":"2009","unstructured":"Borrelli F, Izzo AA. Role of acylethanolamides in the gastrointestinal tract with special reference to food intake and energy balance. Best Pract Res Clin Endocrinol Metab. 2009;23:33\u201349.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"858_CR60","doi-asserted-by":"publisher","first-page":"H1500","DOI":"10.1152\/ajpheart.2000.278.5.H1500","volume":"278","author":"T Langenickel","year":"2000","unstructured":"Langenickel T, Pagel I, Hohnel K, Dietz R, Willenbrock R. Differential regulation of cardiac ANP and BNP mRNA in different stages of experimental heart failure. Am J Physiol Heart Circ Physiol. 2000;278:H1500\u20136.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"858_CR61","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1172\/JCI24178","volume":"115","author":"GW Dorn","year":"2005","unstructured":"Dorn GW. Protein kinase cascades in the regulation of cardiac hypertrophy. J Clin Invest. 2005;115:527.","journal-title":"J Clin Invest"},{"key":"858_CR62","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.cardiores.2004.02.003","volume":"63","author":"CG Proud","year":"2004","unstructured":"Proud CG. Ras, PI3-kinase and mTOR signaling in cardiac hypertrophy. Cardiovasc Res. 2004;63:403\u201313.","journal-title":"Cardiovasc Res"},{"key":"858_CR63","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.yjmcc.2009.04.011","volume":"47","author":"WT Festuccia","year":"2009","unstructured":"Festuccia WT, Laplante M, Br\u00fbl\u00e9 S, Houde VP, Achouba A, Lachance D, et al. Rosiglitazone-induced heart remodelling is associated with enhanced turnover of myofibrillar protein and mTOR activation. J Mol Cell Cardiol. 2009;47:85\u201395.","journal-title":"J Mol Cell Cardiol"},{"key":"858_CR64","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1161\/01.CIR.0000130641.08705.45","volume":"109","author":"JR McMullen","year":"2004","unstructured":"McMullen JR, Sherwood MC, Tarnavski O, Zhang L, Dorfman AL, Shioi T, et al. Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload. Circulation. 2004;109:3050\u20135.","journal-title":"Circulation"},{"key":"858_CR65","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1097\/01.hjh.0000239304.01496.83","volume":"24","author":"X-M Gao","year":"2006","unstructured":"Gao X-M, Wong G, Wang B, Kiriazis H, Moore X-L, Su Y-D, et al. Inhibition of mTOR reduces chronic pressure-overload cardiac hypertrophy and fibrosis. J Hypertens. 2006;24:1663\u201370.","journal-title":"J Hypertens"},{"key":"858_CR66","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1038\/nn.2369","volume":"12","author":"E Puighermanal","year":"2009","unstructured":"Puighermanal E, Marsicano G, Busquets-Garcia A, Lutz B, Maldonado R, Ozaita A. Cannabinoid modulation of hippocampal long-term memory is mediated by mTOR signaling. Nat Neurosci. 2009;12:1152\u20138.","journal-title":"Nat Neurosci"},{"key":"858_CR67","doi-asserted-by":"publisher","first-page":"e80339","DOI":"10.1371\/journal.pone.0080339","volume":"8","author":"LL Senin","year":"2013","unstructured":"Senin LL, Al-Massadi O, Folgueira C, Castelao C, Pardo M, Barja-Fernandez S, et al. The gastric CB1 receptor modulates ghrelin production through the mTOR pathway to regulate food intake. PLoS ONE. 2013;8:e80339.","journal-title":"PLoS ONE"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-022-00858-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-022-00858-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-022-00858-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T19:20:11Z","timestamp":1726687211000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-022-00858-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,21]]},"references-count":67,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["858"],"URL":"https:\/\/doi.org\/10.1038\/s41401-022-00858-x","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,21]]},"assertion":[{"value":"15 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}